Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 25 for your search:

Cancer Type/Condition:  Soft tissue sarcoma, child
Stage/Subtype:  recurrent childhood soft tissue sarcoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: BMT 0499 Solid, NCT00179816

Phase I/II Study of Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12 and Doxorubicin Hydrochloride in Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: UCCRC-16227A, 16227A, 8131, NCT00720174

Phase I/II Study of Dasatinib in Combination With Ifosfamide, Carboplatin, and Etoposide Phosphate in Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: J0963, NA_00028490, NCT00949325

Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Other
Protocol IDs: INST 0909, 3066K1, 3066K1-1208, 20091334, NCT00996346

Phase II Pilot Study of Induction Chemotherapy Followed By Allogeneic/Syngeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk, Recurrent Pediatric Sarcoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 4 to 35
Sponsor: NCI
Protocol IDs: NCI-02-C-0259, NCT00047372

Phase II Study of Ecteinascidin 743 in Pediatric Patients With Recurrent or Refractory Soft Tissue Sarcomas or Ewing's Sarcoma Family of Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 21 (at time of diagnosis)
Sponsor: NCI
Protocol IDs: COG-ADVL0221, NCT00070109, ADVL0221

Radiation Therapy to Treat Musculoskeletal Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992

Phase II Study of Intrathecal Iodine I 131 Monoclonal Antibody 3F8 in Patients With GD2-Expressing Central Nervous System or Leptomeningeal Neoplasms

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965

10.

Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187

11.

Trial of Dasatinib in Advanced Sarcomas

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 13
Sponsor: Other
Protocol IDs: SARC009, NCT00464620

12.

Phase 2 Study in Patients With MiT Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-204, NCT00557609

13.

Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas

Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293

14.

A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent

Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP13-0707, EudraCT Number: 2007-006719-21, NCT00668148

15.

Phase II Study of Cixutumumab in Patients With Relapsed or Refractory Solid Tumors

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 30 years
Sponsor: NCI
Protocol IDs: COG-ADVL0821, ADVL0821, NCT00831844

16.

A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.

Phase: Phase II
Type: Treatment
Status: Active
Age: 2 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NO21157, SARC011, NCT00642941

17.

Phase I Study of Ixabepilone in Young Patients With Refractory Solid Tumors (Closed to Accrual as of 10/4/2007) or Relapsed or Refractory Leukemia

Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-02-C-0031, 02-C-0031, 5425, NCI-5425, NCT00030108

18.

Phase I Study of Intrathecal Iodine I 131 Monoclonal Antibody 8H9 in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MSKCC-03133, NCT00089245

19.

Phase I Study of Cediranib in Pediatric Patients With Refractory or Recurrent Extracranial Malignant Solid Tumors or Acute Myeloid Leukemia

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-06-C-0152, NCI-P6571, NCT00354848, ZENECA-D8480C00016

20.

Phase I Study of Lexatumumab With or Without Recombinant Interferon Gamma in Pediatric Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI
Protocol IDs: NCI-07-C-0040, NCI-P6981, NCT00428272

21.

Phase I Study of Trabectedin in Pediatric Patients With Relapsed or Refractory Solid Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 4 to 16
Sponsor: NCI
Protocol IDs: NCI-07-C-0054, NCT00437047

22.

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Patients With Advanced or Refractory Solid Tumors

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-08-C-0007, 08-C-0007, NCI-P6068, 7458, NCT00556881

23.

Phase I Study of Total Marrow Irradiation With Helical Tomotherapy Image-Guided Intensity-Modulated Radiotherapy Followed by Alkylator-Intense Conditioning Comprising Busulfan, Melphalan, and Thiotepa and Autologous CD34+ Hematopoietic Progenitor Cell Transplantation in Patients With High-Risk or Relapsed Solid Tumors

Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 70 and under
Sponsor: NCI
Protocol IDs: UMN-2005LS023, UMN-2005LS023, UMN-MT2004-30, NCT00623077

24.

Phase I Study of Pazopanib Hydrochloride in Pediatric Patients With Refractory Solid Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: COG-ADVL0815, ADVL0815, NCT00929903

25.

Pilot Study of Cyclophosphamide and Cryoablation in Patients With Advanced or Metastatic Epithelial Solid Cancer

Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: JHOC-J0685, NA_00003073, J0685, NCT00499733

Select All on Page

Help with Results

A Service of the National Cancer Institute